Format
Sort by
Items per page

Send to

Choose Destination

Best matches for FILGRASTIM/TU:

A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Dale DC et al. Support Care Cancer. (2018)

Tbo-Filgrastim: A Review in Neutropenic Conditions. Blair HA et al. BioDrugs. (2016)

Conversion from Filgrastim to Tbo-filgrastim: Experience of a Large Health Care System. Agboola F et al. J Manag Care Spec Pharm. (2017)

Search results

Items: 1 to 20 of 242

1.

Safety and Relative Dose Intensity of Dose-dense Doxorubicin and Cyclophosphamide Followed by Dose-dense Paclitaxel.

Nishimura M, Onoe T, Sakai H, Arase M, Watanabe S, Soyama M, Hashimoto K, Miki M, Tane K, Hirokaga K, Takao S, Matsumoto K.

Anticancer Res. 2019 Aug;39(8):4379-4383. doi: 10.21873/anticanres.13607.

PMID:
31366533
2.

[Comparison of Pegfilgrastim and Filgrastim for the Primary Prophylactic Effect for Preventing Febrile Neutropenia in Patients Undergoing Rituximab with Dose-adjusted EPOCH Chemotherapy].

Kataoka T, Sakurashita H, Taogoshi T, Nishigakiuchi R, Murase T, Izumitani S, Saeki Y, Matsuo H.

Yakugaku Zasshi. 2019;139(4):629-633. doi: 10.1248/yakushi.18-00101. Japanese.

3.

[Identification of the Risk Factors for Cabazitaxel-Induced Neutropenia with Preventive Administration of Pegfilgrastim].

Kageyama A, Nakazawa Y, Ando N, Harada D, Kitamura M, Kawakubo T, Asano K.

Gan To Kagaku Ryoho. 2019 Feb;46(2):279-281. Japanese.

PMID:
30914534
4.
5.

LA-EP2006: A Pegfilgrastim Biosimilar.

Hoy SM.

BioDrugs. 2019 Apr;33(2):229-232. doi: 10.1007/s40259-019-00348-3. Review.

PMID:
30887256
6.

The evolution of value with filgrastim in oncology.

Cornes P, Krendyukov A.

Future Oncol. 2019 May;15(13):1525-1533. doi: 10.2217/fon-2018-0762. Epub 2019 Mar 5. Review.

7.

Safety analysis of proposed pegfilgrastim biosimilar in Phase I and Phase III studies.

Harbeck N, Wang J, Otto GP, Gattu S, Krendyukov A.

Future Oncol. 2019 Apr;15(12):1313-1322. doi: 10.2217/fon-2018-0878. Epub 2019 Mar 5.

8.

Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study.

Ludwig H, Bokemeyer C, Aapro M, Boccadoro M, Gascón P, Denhaerynck K, Krendyukov A, Abraham I, MacDonald K.

Future Oncol. 2019 Mar;15(8):897-907. doi: 10.2217/fon-2018-0814. Epub 2019 Mar 4.

9.

Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia.

Waller CF, Ranganna GM, Pennella EJ, Blakeley C, Bronchud MH, Mattano LA Jr, Berzoy O, Voitko N, Shparyk Y, Lytvyn I, Rusyn A, Popov V, Láng I, Beckmann K, Sharma R, Baczkowski M, Kothekar M, Barve A.

Ann Hematol. 2019 May;98(5):1217-1224. doi: 10.1007/s00277-019-03639-5. Epub 2019 Mar 1.

10.

[Successful Treatment of Advanced Esophageal Cancer with DCF Chemotherapy and Pegfilgrastim].

Gunjigake K, Okamoto K, Gabata R, Yamaguchi T, Ninomiya I, Fushida S, Ohta T.

Gan To Kagaku Ryoho. 2019 Jan;46(1):61-63. Japanese.

PMID:
30765644
11.
12.

Pegfilgrastim-jmdb/MYL-1401H: A Pegfilgrastim Biosimilar.

Hoy SM.

BioDrugs. 2019 Feb;33(1):117-120. doi: 10.1007/s40259-019-00334-9. Review.

PMID:
30701419
13.

Monocytopenia in clozapine-induced agranulocytosis: insights into pathophysiology and treatment.

Patel R, Lima A, Burke C, Hoffman M.

BMJ Case Rep. 2019 Jan 18;12(1). pii: bcr-2018-226016. doi: 10.1136/bcr-2018-226016.

PMID:
30661042
14.

[A Case of Arteritis That Developed after Pegfilgrastim Administration during Chemotherapy for Breast Cancer].

Chino T, Oba T, Yamamoto K, Takekoshi D, Iesato A, Ito T, Kanai T, Maeno K, Ito K.

Gan To Kagaku Ryoho. 2018 Dec;45(12):1771-1774. Japanese.

PMID:
30587739
15.

[Safety Profile of the Combination of Prophylactic Pegfilgrastim and Cabazitaxel for Japanese Patients with Castration Resistant Prostate Cancer].

Azuma K, Kawakami K, Yuasa T, Sugisaki T, Hashimoto K, Aoyama T, Suzuki K, Yonese J, Hama T.

Gan To Kagaku Ryoho. 2018 Dec;45(12):1737-1742. Japanese.

PMID:
30587731
16.

[Impact of Primary Prophylaxis with Pegfilgrastim on Clinical Outcomes in Patients with Advanced Esophageal Cancer Receiving Chemotherapy with Docetaxel, Cisplatin ,and 5-FU].

Yasuda T, Ishikawa T, Ohta T, Yoshida J, Doi T, Dohi O, Okayama T, Yoshida N, Kamada K, Uchiyama K, Handa O, Takagi T, Konishi H, Shiozaki A, Fujiwara H, Naito Y, Itoh Y.

Gan To Kagaku Ryoho. 2018 Dec;45(12):1733-1736. Japanese.

PMID:
30587730
17.

[Utility of Prophylactic Administration of Pegfilgrastim in Breast Cancer Chemotherapy].

Norimura S, Kontani K, Morishita A, Kubo T, Murazawa C, Hashimoto S, Hashimoto N, Kenzaki K, Miura K, Yokomise H.

Gan To Kagaku Ryoho. 2018 Dec;45(12):1729-1732. Japanese.

PMID:
30587729
18.

Efficacy and Safety of Biosimilar Filgrastim for Cord Blood Transplantation: A Single-Institution Retrospective Analysis.

Iino M, Yamamoto T.

Transplant Proc. 2018 Dec;50(10):3804-3810. doi: 10.1016/j.transproceed.2018.06.036. Epub 2018 Jun 30.

PMID:
30577272
19.

Neulasta Regimen for the Hematopoietic Acute Radiation Syndrome: Effects Beyond Neutrophil Recovery.

Legesse B, Kaur A, Kenchegowda D, Hritzo B, Culp WE, Moroni M.

Int J Radiat Oncol Biol Phys. 2019 Mar 15;103(4):935-944. doi: 10.1016/j.ijrobp.2018.11.043. Epub 2018 Nov 26.

PMID:
30496878
20.

Comparison of filgrastim, pegfilgrastim, and lipegfilgrastim added to chemotherapy for mobilization of CD34+ cells in non-Hodgkin lymphoma patients.

Partanen A, Valtola J, Ropponen A, Kuitunen H, Kuittinen O, Vasala K, Ågren L, Penttilä K, Keskinen L, Pyörälä M, Nousiainen T, Selander T, Mäntymaa P, Pelkonen J, Varmavuo V, Jantunen E.

Transfusion. 2019 Jan;59(1):325-334. doi: 10.1111/trf.14993. Epub 2018 Nov 19.

PMID:
30450652

Supplemental Content

Loading ...
Support Center